Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 28085669.
- Also identified by DOI 10.1016/j.eururo.2016.10.023.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a recent trial, adjuvant treatment with sunitinib significantly prolonged disease-free survival compared to placebo. This positive result is muted by the rate of side effects and overtreatment, raising the question of proper patient and agent selection in the adjuvant setting.
Medical subject headings
- Carcinoma, Renal Cell
- Chemotherapy, Adjuvant
- Kidney Neoplasms
- Nephrectomy
- Protein Kinase Inhibitors